Moderna, Inc. (MRNA) earnings date
Feb 18, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 27% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 34 days, typically, give or take 6 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Fri, Nov 6, 2026 | before open | 37 | 8-K |
| Q2 FY2026 | Fri, Jul 31, 2026 | before open | 31 | 8-K |
| Q1 FY2026 | Fri, May 1, 2026 | before open | 31 | 8-K |
| Q4 FY2025 | Fri, Feb 13, 2026 | before open | 44 | 8-K |
| Q3 FY2025 | Thu, Nov 6, 2025 | before open | 37 | 8-K |
| Q2 FY2025 | Fri, Aug 1, 2025 | before open | 32 | 8-K |
| Q1 FY2025 | Thu, May 1, 2025 | before open | 31 | 8-K |
| Q4 FY2024 | Fri, Feb 14, 2025 | before open | 45 | 8-K |
What they guided beta
| Q3 FY2026 | "Document Exhibit 99.1 Moderna Reports Third Quarter 2026 Financial Results and Provides Business Updates Reports third quarter revenue of $1.3 billion, GAAP net income of $0.2 billion and GAAP diluted EPS of $0.38 Increases 2026 expected revenue growth to 15%–25%, exceeding the previous expectation of up to 10% growth Improves 2026 GAAP operating expense outlook by approximately $0.2 billion from previous estimate Increases 2026 expected ending cash balance to $8.1–$8.3 billion Highlights positive Phase 3 data for intismeran and U.S. FDA approval of mFLUSIVA, the Company's fifth approved produ" exhibit |
| Q3 FY2026 | "“Building on this momentum, we increased our full-year revenue growth outlook to 15%-25%, while continuing to reduce costs and strengthen our balance sheet." exhibit |
| Q3 FY2026 | "Cost of sales increased by 54% compared to the same period in 2025, primarily driven by higher product sales volume and other manufacturing-related costs. 1 Research and Development Expenses: Research and development expenses for the third quarter of 2026 were $583 million, a 27% decrease compared to the same period in 2025, primarily driven by lower clinical development costs following the completion and wind-down of certain late-stage studies in the Company's infectious disease portfolio, as well as continued cost efficiencies across the organization." exhibit |
| Q3 FY2026 | "The increase primarily reflected $2.6 billion in net proceeds from the issuance of convertible notes and related capped call transactions, partially offset by the $950 million payment related to the litigation settlement announced in the first quarter of 2026, and cash used in operations, including the seasonal working capital impact from third-quarter product sales, the majority of which remained uncollected at quarter-end. 2026 Financial Framework Revenue: The Company now expects total revenue growth of 15% to 25% in 2026, exceeding its previous outlook of up to 10% growth." exhibit |
| Q3 FY2026 | "Moderna continues to expect approximately half of its 2026 revenue to come from the United States and half from international markets." exhibit |
| Q2 FY2026 | "Document Exhibit 99.1 Moderna Reports Second Quarter 2026 Financial Results and Provides Business Updates Reports second quarter revenue of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(1.97) Reiterates plan to deliver up to 10% revenue growth in 2026 Improves 2026 GAAP operating expense outlook by approximately $0.2 billion from previous estimate and improves expected 2026 year-end cash balance to $4.7 - 5.2 billion Anticipates potential approval of Moderna's fifth product with the August 5th PDUFA date for mFLUSIVA, the Company's seasonal influenza vaccine candidate Announc" exhibit |
| Q2 FY2026 | ""The second quarter marked another period of strong execution for Moderna as we advanced our pipeline and strengthened our financial profile with an improved 2026 operating expense outlook," said Stéphane Bancel, Chief Executive Officer of Moderna." exhibit |
| Q2 FY2026 | ""In the second half of 2026, we are preparing for the potential approval of mFLUSIVA in the U.S., which would be our fifth approved product, and continue to anticipate important pivotal readouts for our intismeran in melanoma and propionic acidemia programs." Commercial Updates During the second quarter, Moderna continued to advance its multi-year revenue growth strategy by executing on strategic partnerships and key approvals." exhibit |
| Q2 FY2026 | "Cost of sales decreased by 22% compared to the same period in 2025, primarily reflecting lower unutilized manufacturing capacity costs resulting from continued manufacturing productivity improvements and operational efficiencies." exhibit |
| Q2 FY2026 | "The Company subsequently paid $950 million in July 2026 related to the litigation settlement announced in the first quarter of 2026. 2026 Financial Framework Revenue: The Company is targeting up to 10% growth from 2025 revenue and expects 2026 revenue split to be approximately 50% U.S. and approximately 50% international." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/MRNA
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/MRNA
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/MRNA/"><img src="https://veritasdata.dev/embed/MRNA.svg" alt="MRNA earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/MRNA/)
Script
<script async src="https://veritasdata.dev/embed/MRNA.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/MRNA"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.